Dr Ducu Botoaca, who has a central London aesthetics clinic, told the MailOnline that he has seen a worrying increase in ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

PepsiCo, Inc. (NASDAQ: PEP) is one of the stocks that Jim Cramer recently commented on. During the episode, Cramer noted that ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

A spokesperson said: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped.

Shona also quoted doctor Tom Hildebrandt, who said he was seeing an increase in patients with eating disorders taking ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

When you hear the name Ozempic, you likely think of diabetes treatment. That makes sense, as semaglutide was first approved in 2017 to help people with type 2 diabetes regulate […] ...

Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...